MONTREAL, December 5th, 2019 – Replicor Inc., a privately held biopharmaceutical company targeting functional cure for patients with chronic hepatitis B and D infection, announced that three presentations will be made at the 2019 HEPDART meeting to be held December 8-12th , 2019 in Kauai, HI, USA.
One oral presentation on December 9th and two posters on December 10th will cover the following:
Disclosure of the final completed follow-up results from the REP 301-LTF and REP 401 studies, showing high rates of stable functional cure of HBV and HDV infection.
Analysis showing the safe and beneficial relationship between transaminase flares occurring in the absence of HBsAg during NAP-based combination and the ability of this on-therapy milestone to predict virologic control and functional cure of HBV and HDV infection.
Replicor’s presentations will be made available following their publication on the company’s website at www.replicor.com/science/conference-presentations. For further information about the 2019 HEPDART Meeting: https://hepdart.com/
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at www.replicor.com.